Stay updated on XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial
Sign up to get notified when there's something new on the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page.

Latest updates to the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page
- Check5 days agoChange DetectedThe page now lists Revision: v3.3.4 and no longer shows Revision: v3.3.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedAdded a Locations section with Massachusetts as a study site and updated the page revision to v3.3.3. Removed HHS Vulnerability Disclosure and several related topics (including MedlinePlus Genetics and Massachusetts Locations) from the page.SummaryDifference0.4%

- Check34 days agoChange DetectedAdded Prostate cancer and related topics: MedlinePlus Genetics to the study page to improve context and navigation.SummaryDifference0.2%

- Check41 days agoChange DetectedProstate cancer and related topics: MedlinePlus Genetics have been removed from the page.SummaryDifference0.2%

- Check48 days agoChange DetectedAdded related topics Prostate cancer and MedlinePlus Genetics, and updated the page revision from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check55 days agoChange DetectedThe changes are only revision numbers in the page footer (Revision: v3.3.1 added and v3.2.0 removed), with no modifications to the study details or other page content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XL-184+Abiraterone in Post-Chemo CRPC Clinical Trial page.